Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Y. Kito; T. Yamada; T. Matsumoto; H. Yasui; K. Murata; A. Makiyama; H. Hara; E. Baba; K. Nishio; K. Yoshimura; S. Hironaka; K. Muro; K. Yamazaki

doi:10.1093/annonc/mdy281.151

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Y. Kito, T. Yamada, T. Matsumoto, H. Yasui, K. Murata, A. Makiyama, H. Hara, E. Baba, K. Nishio, K. Yoshimura, S. Hironaka, K. Muro, K. Yamazaki

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	viii201
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy281.151
Publication status	Published - Oct 1 2018

All Science Journal Classification (ASJC) codes

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy281.151

Cite this

Kito, Y., Yamada, T., Matsumoto, T., Yasui, H., Murata, K., Makiyama, A., Hara, H., Baba, E., Nishio, K., Yoshimura, K., Hironaka, S., Muro, K., & Yamazaki, K. (2018). Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii201. https://doi.org/10.1093/annonc/mdy281.151

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC) : WJOG9216G. / Kito, Y.; Yamada, T.; Matsumoto, T. et al.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii201.

Research output: Contribution to journal › Article › peer-review

Kito, Y, Yamada, T, Matsumoto, T, Yasui, H, Murata, K, Makiyama, A, Hara, H, Baba, E, Nishio, K, Yoshimura, K, Hironaka, S, Muro, K & Yamazaki, K 2018, 'Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii201. https://doi.org/10.1093/annonc/mdy281.151

Kito Y, Yamada T, Matsumoto T, Yasui H, Murata K, Makiyama A et al. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii201. doi: 10.1093/annonc/mdy281.151

@article{6d553fc902ad44228e92944dec8d1674,

title = "Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G",

author = "Y. Kito and T. Yamada and T. Matsumoto and H. Yasui and K. Murata and A. Makiyama and H. Hara and E. Baba and K. Nishio and K. Yoshimura and S. Hironaka and K. Muro and K. Yamazaki",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy281.151",

language = "English",

volume = "29",

pages = "viii201",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC)

T2 - WJOG9216G

AU - Kito, Y.

AU - Yamada, T.

AU - Matsumoto, T.

AU - Yasui, H.

AU - Murata, K.

AU - Makiyama, A.

AU - Hara, H.

AU - Baba, E.

AU - Nishio, K.

AU - Yoshimura, K.

AU - Hironaka, S.

AU - Muro, K.

AU - Yamazaki, K.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530641&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy281.151

DO - 10.1093/annonc/mdy281.151

M3 - Article

C2 - 32136419

SN - 0923-7534

VL - 29

SP - viii201

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this